ZSAN - Zosano formulates COVID-19 vaccine candidate using patch technology

Zosano Pharma (NASDAQ:ZSAN) has gained ~12.5% in the pre-market after the company announced the successful formulation of a COVID-19 vaccine candidate using its microneedle patch system. Zosano’s patch, consisting of a range of nearly two thousand drug-coated titanium microneedles, is administered to the skin using a reusable applicator, according to the company. Mahmoud Ameri, vice president of research and development at Zosano (ZSAN), predicted that a COVID-19 vaccine candidate based on its patch technology could be an alternative to traditional intramuscular injections. The company CEO Steve Lo said that Zosano (ZSAN) was looking forward to building non-dilutive and partnership opportunities to further expand the technology.

For further details see:

Zosano formulates COVID-19 vaccine candidate using patch technology